Why Repros Therapeutics Inc. Shares Were Decimated

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Repros Therapeutics (NASDAQ: RPRX  ) , a clinical-stage company developing therapies to treat hormonal and reproductive system disorders, plunged as much as 32% after delaying the filing of its new drug application for Androxal for several months.

So what: According to this morning's press release from Repros, it is planning to forgo filing a new drug application for its hypogonadism treatment Andorxal, which was expected by mid-2014, and will hold off until the fourth quarter of 2014. The reason for the move is that the Food and Drug Administration wants a year's worth of safety data on the highest dosage of Androxal, which will require Repros to run two additional trials. But, it wasn't all negative news, either. The press release also noted that if Androxal proved markedly superior to competing testosterone treatments in these two trials, that the FDA would consider an expedited NDA review.

Now what: Today is nothing more than traders hoping for a quick approval getting the shaft. Nothing has materially changed in the underlying data of Androxal other than Repros' need to run two additional trials utilizing the highest dosage. In other words, until there's a fire, you don't need to call the fire department!

Despite the several month delay, I feel today's move is based more on emotion than on logic given the success of Androxal in trials to date. As such, I would certainly suggest biotech-savvy investors give a closer look to Repros after today's drop.

The best way to play the biotech sector
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 23, 2013, at 5:13 PM, drjoe56 wrote:

    It is stuff like this that makes me want to get out the stock market.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2695579, ~/Articles/ArticleHandler.aspx, 9/29/2016 9:51:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 35 minutes ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
RPRX $2.11 Up +0.02 +0.96%
Repros Therapeutic… CAPS Rating: *